Synageva Biopharma Corp.

Synageva Biopharma Corp. company information, Employees & Contact Information

Synageva BioPharma is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for people living with rare diseases of high unmet medical need. We are passionate about our commitment to improving their lives and those of their families for generations to come. Our experienced team has helped bring several life-saving therapies for diseases that were once considered too rare for development treatments. We believe that every patient deserves treatment options, no matter how rare their disease. We believe that when it comes to delivering innovative therapies, Every Second Counts.

Company Details

Employees
20
Address
33 Hayden Ave, Lexington,massachusetts 02421,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lexington, Massachusetts
Looking for a particular Synageva Biopharma Corp. employee's phone or email?

Synageva Biopharma Corp. Questions

News

Synageva BioPharma To Present At The Cowen and Company Health Care Conference - PR Newswire

Synageva BioPharma To Present At The Cowen and Company Health Care Conference PR Newswire

Alexion pays big for Synageva's rare disease drug candidate - Nature

Alexion pays big for Synageva's rare disease drug candidate Nature

Synageva BioPharma To Present At J.P. Morgan Conference; Webcast At 1:30 PM ET - RTTNews

Synageva BioPharma To Present At J.P. Morgan Conference; Webcast At 1:30 PM ET RTTNews

Biotech blastoff: Synageva up 112% on $8B Alexion deal - USA Today

Biotech blastoff: Synageva up 112% on $8B Alexion deal USA Today

Alexion to bolster rare disease offering with $8.4 billion deal - Reuters

Alexion to bolster rare disease offering with $8.4 billion deal Reuters

Alexion Bets $8.4 Billion on Synageva in Rare-Disease Push - Bloomberg.com

Alexion Bets $8.4 Billion on Synageva in Rare-Disease Push Bloomberg.com

Alexion to Buy Synageva BioPharma in $8.4 Billion Deal (Published 2015) - The New York Times

Alexion to Buy Synageva BioPharma in $8.4 Billion Deal (Published 2015) The New York Times

Alexion to Acquire Synageva for $8.4 billion - Genetic Engineering and Biotechnology News

Alexion to Acquire Synageva for $8.4 billion Genetic Engineering and Biotechnology News

Despite no drugs on market, Lexington biotech fetches $8b - The Boston Globe

Despite no drugs on market, Lexington biotech fetches $8b The Boston Globe

Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer - PR Newswire

Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer PR Newswire

Alexion to buy Synageva for $8.4bn - Financial Times

Alexion to buy Synageva for $8.4bn Financial Times

Large Pharma Acquisition -- Alexion Buys Synageva for $8.4 Billion - IndustryWeek

Large Pharma Acquisition -- Alexion Buys Synageva for $8.4 Billion IndustryWeek

Everything you need to know about the $8.4 B acquisition of Synageva - The Business Journals

Everything you need to know about the $8.4 B acquisition of Synageva The Business Journals

Synageva Merges with Trimeris in All-Stock Deal - Genetic Engineering and Biotechnology News

Synageva Merges with Trimeris in All-Stock Deal Genetic Engineering and Biotechnology News

Synageva Reveals Data From Extension Study Of Sebelipase Alfa - RTTNews

Synageva Reveals Data From Extension Study Of Sebelipase Alfa RTTNews

Top Synageva Biopharma Corp. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant